REFERENCES: 1. FeRiva 21/7™ Prescribing Information, Avion Pharmaceuticals, LLC, 2014. 2. Kamdi SP, Palkar PJ. Efficacy and safety of ferrous asparto glycinate in the management of iron deficiency anaemia in pregnant women. J Obstet Gynaecol. 2014; Early Online: 1–5. doi:10.3109/01443615.2014.930098. Accessed December 29, 2014. 3. Data on File. Avion Pharmaceuticals LLC, Alpharetta, GA. 4. Bovell-Benjamin AC, Viteri FE, and Allen LH. Iron absorption from ferrous bisglycinate and ferric trisglycinate in whole maize is regulated by iron status. Am J Clin Nutr. 2000; 71:1563–1569. 5. Pineda O, Ashmead HD, Perez JM, Lemus CP. Effectiveness of iron amino acid chelate on the treatment of iron deficiency anemia in adolescents. J App Nutr. 1994; 46(1,2):2-13. 6. Brise H, Hallberg L. Effect of ascorbic acid on iron absorption. Act Med Scan. 1962; 171(suppl 376):51-58. 7. Brise H, Hallberg L. Effect of succinic acid on iron absorption. Acta Med Scand. 1962; 171(suppl 376):59-73. 8. Hallberg L, Norrby A, Solvell L. Oral iron with succinic acid in the treatment of iron deficiency anaemia. Scan J Haematol. 1971; 8:104-111. 9. Zariwala MG, Somavarapu S, Farnaud S, Renshaw D. Comparison study of oral iron preparations using a human intestinal model. Sci Pharm. 2013; 81:1123–1139. 10. Devasthali SD, Gordeuk VR, Brittenham GM, Bravo JR, Hughes MA, Keating LJ. Bioavailability of carbonyl iron: A randomized, double-blind study. Eur J Haematol. 1991; 46: 272-278. 11. See, Pineda O. at n. 1, supra. This chart assumes that the Ferrous bisGlycinate Chelate, as indicated, has a bioavailability profile equivalent to Ferrochel®, the subject of Pineda.